Abstract:4633 This study focuses on tumor cell survival and angiogenesis after tumor cell intravasation of vasculature. Dynamic monitoring was performed using the mouse lung metastasis model treated with platelet activation inhibitor (PGI2) and VEGFR inhibitor (SU5416). 3x105 DiI labeled LLC (Lewis lung carcinoma) cells were injected into the tail veins of C57BL6J mice to develop tumor metastasis in lung. The experimental animals were divided into control, PGI2 (100ug/mouse, once), and SU5416 (25mg/kg daily, for 5 days) groups. Lung, liver, and spleen frozen sections were cut and stained with DAPI at 15 min, 24 hours, 4 days, 8 days, 13 days and 15 days after injection of LLC cells for fluorescence microscopy assay. A similar experiment was performed (5 mice each group) and lung and liver were investigated at 15 days after injection of LLC cells for metastasis tumor colonies. A novel vivo and vitro combination technique was developed to test platelet active LLC cells binding on HUVEC capillary-like structures. The capability of VEGFR inhibitor (SU 5416) in blocking new vasculature development was tested in a mouse dorsal vascular window model. The dynamic monitoring shows that DiI labeled LLC cells accumulated in the lungs of all treatment groups (with slightly less accumulation in mice treated with PGI2). Very little DiI labeled LLC cells accumulated in liver and spleen at 15 min after injection. At the 24 hours and 4 days time points, DiI( red ) density was increasing in liver and spleen, but decreased at 8 day, 13 day, and 15 day time points. Meanwhile, DiI density in lung was changing with time, treatment, and tumor cell survival. Lung surface tumor colony counts show that there are 40-50 times more colonies in control lungs than SU5416 and combination groups, and the weights of lungs are also significantly different. Histology evidence is consistent with the above results. PGI2 significantly reduced LLC cell binding to HUVEC capillary-like structures (10 times lower). The dorsal window model with LLC cells showed that treatment with 5 doses of the VEGFR inhibitor SU5416 (3 mice) completely impeded angiogenesis compared to the control (3 mice). Conclusions: 1).The first several days are crucial in LLC cells developing metastasis in lung after intravasation. 2). VEGFR inhibitor (SU5416) can significantly prevent LLC cells from developing metastasis in lung. 3). Platelet activation inhibitor (PGI2) efficiently reduces LLC cell adhesion on endothelium (HUVEC). 4). VEGFR inhibitor (SU5416) is seemingly more effective than platelet activation inhibitor (PGI2) in impeding LLC lung metastasis formation after intravasation.

Dynamic Monitoring of LLC Lung Metastasis Development and Prevention

Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model.

Platelet P2Y12 is Involved in Murine Pulmonary Metastasis.

PLGF Regulates Crosstalk Between Non-Small Cell Lung Cancer Cells and Tumor-Associated Macrophages in Cancer Vascularization and Growth

Effects of VEGFR1+ hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells

Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice

Eftect of Lewis lung cancer on mouse intestinal stem cells and their microenvironment

A Humanized Single-Chain Antibody Against Beta 3 Integrin Inhibits Pulmonary Metastasis by Preferentially Fragmenting Activated Platelets in the Tumor Microenvironment

Differential Drug Class‐specific Metastatic Effects Following Treatment with a Panel of Angiogenesis Inhibitors

Disrupting Tumour Vasculature and Recruitment of Apdl1-Loaded Platelets Control Tumour Metastasis

SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/Akt signaling pathway

A novel lung cancer stem cell extracellular vesicles lncRNA ROLLCSC modulate non-stemness cancer cell plasticity through miR-5623-3p and miR-217-5p targeting lipid metabolism

Histological Study of the Features of Angiogenesis Lewis Lung Carcinoma under the Influence of Mesenchymal Stem Cells of the Placenta

Human mesenchymal stem cells increase LLC metastasis and stimulate or decelerate tumor development depending on injection method and cell amount

Systemic Inhibition of Tumor Growth by Soluble Flk-1 Gene Therapy Combined with Cisplatin

Abstract 4037: Optimizing the efficacy of anti-VEGF/cytotoxics/anti-PD-1 scheduling in a lung cancer mice model through B and T cells monitoring

Antitumor Activity and Immunomodulatory Effects of the Intraperitoneal Administration of Kanglaite in Vivo in Lewis Lung Carcinoma

Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer

Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer

Tumor-infiltrating platelets promote the growth of lung adenocarcinoma

In Vivo Tagging of Lung Epithelial Cells to Define the Early Steps of Tumor Cell Dissemination